Rusfertide: 32-week primary endpoint data from P3 VERIFY trial (NCT05210790) for polycythemia vera in March 2025 (Protagonist Therapeutics) - Jan 19, 2025 - Corporate Presentation
P3 data • Hematological Malignancies • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera
|